Pristimerin inhibited the expression and translocation of p65, the phosphorylation of IκBα and the activation of IKKα/β, identifying the inhibition of constitutive NF-κB pathway in CRC (20), pancreatic cancer (41), CML (43), ESCC (86), and multiple myeloma tumors (108). Here, NFKB1 is linked to familial pancreatic carcinoma.